BioDelivery Sciences (BDSI) shareholders got some welcome good news today, with positive phase 3 top-line data for BEMA buprenorphine sending shares up 9% as of this writing.
The drug provided a statistically significant improvment in chronic pain relief versus placebo, and the trial's completion triggered a $10 million payment from commercialization partner Endo International (ENDP). So, considering today's good news, should investors think about buying BioDelivery stock?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give more details on the drug and whether this makes BioDelivery Sciences a stock to buy.
